Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00988091 · ClinicalTrials.gov registry record · Phase 3
Investigation of 1.2% Sodium Hyaluronate for Treatment of Painful Chronic Osteoarthritis of the Knee
A Phase 3 study, sponsored by Ferring Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 596
- Enrollment target
NCT00988091 is a Phase 3 study that has completed, run by Ferring Pharmaceuticals. The registered enrollment target is 596 participants.
The verdict
NCT00988091, a Phase 3 study, has completed, sponsored by Ferring Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 596 participants
- Enrollment target
Study Summary
Subjects with chronic osteoarthritis of the knee will be assigned to receive an injection of either 1.2% sodium hyaluronate or buffered saline to evaluate its effectiveness and safety for 26 weeks. After 26 weeks, subjects can elect to receive a second injection of 1.2% sodium hyaluronate and be followed for another 26 weeks.
Interventions
- DEVICE 1.2% Sodium Hyaluronate
- DEVICE Buffered Saline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 596 participants |
| Start Date | 2009-09 |
| Est. Completion | 2011-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00988091
The ClinicalTrials.gov registry entry for NCT00988091 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 596 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ferring Pharmaceuticals, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 1.2% Sodium Hyaluronate is the first listed.
NCT00988091 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00988091 about?
NCT00988091 is a clinical study titled "Investigation of 1.2% Sodium Hyaluronate for Treatment of Painful Chronic Osteoarthritis of the Knee". Subjects with chronic osteoarthritis of the knee will be assigned to receive an injection of either 1.2% sodium hyaluronate or buffered saline to evaluate its effectiveness and safety for 26 weeks. After 26 weeks, subjects can elect to receive a second injection of 1.2% sodium hyaluronate and be fol...
What is the current status of trial NCT00988091?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 596 participants. The study started on 2009-09. Estimated completion is 2011-04.
What interventions are being tested in trial NCT00988091?
The interventions under investigation include: 1.2% Sodium Hyaluronate (DEVICE), Buffered Saline (DEVICE).
Who is sponsoring clinical trial NCT00988091?
This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.